A Novel Cell Selective Lentiviral Platform For In Vivo CAR-T Engineering

Targeted gene delivery is reshaping how CAR‑T therapies can be developed and deployed. By enabling selective transduction of defined T‑cell populations, targeted lentiviral vectors open the door to faster, simpler, and more accessible immunotherapies. Discover a paramyxovirus‑pseudotyped LVV platform engineered to efficiently deliver genes to non‑activated T cells, both ex vivo and directly in vivo. Through precise retargeting of viral entry using cell‑specific binding domains, the approach supports selective generation of CD4‑, CD8‑, or pan‑T‑cell CAR‑T subsets. High‑titer vector production and optimized transfection enable robust CAR‑T generation, potent tumor cell killing in vitro, and rapid B‑cell depletion in vivo.

Together, these findings point toward a streamlined CAR‑T manufacturing paradigm with reduced complexity, lower cost, and broader patient access. Explore how targeted LVVs could redefine next‑generation CAR‑T therapy workflows.